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Open acEvidence supporting a beneﬁcial role of vitamin D in chronic
hepatitis CTo the Editor:
We read with interest the recent meta-analysis by Kitson et al.
[1]. The authors show that baseline vitamin D level is not associ-
ated with sustained virologic response (SVR) to pegylated inter-
feron (PegIFN) plus ribavirin therapy in patients with chronic
hepatitis C (CHC). Based on this ﬁnding, they question [1] the
non-skeletal beneﬁts of vitamin D supplements, an essential
determinant in regulating bone metabolism in chronic liver
disease [2], on CHC. However, as vitamin D deﬁciency has been
identiﬁed as a main risk factor for CHC development, we believe
that the non-skeletal beneﬁts of this kind of vitamin on patients
with CHC cannot be negligible and the conclusions of this meta-
analysis [1] needs to be further discussed and researched.
First, the studies included in the meta-analysis by Kitson et al.
[1] were performed in patients from America, Europe, Australia,
or Israel, all of whom were predominantly white in skin color.
Interestingly, a community-based cross-sectional study showed
that, compared with white people, blacks had lower levels of
vitamin D and vitamin D-binding protein [3]. In addition, poten-
tial differences were also observed between whites and blacks in
relation to the inﬂuence of vitamin D status in the degree of
hepatic ﬁbrosis in CHC patients [4]. As a consequence, levels of
vitamin D and its beneﬁts may vary in individuals with different
ethnicity, therefore the irrelevance between vitamin D and SVR,
and the ineffectiveness of vitamin D in CHC shown in this study,
needs to be also conﬁrmed in other races.
Second, this meta-analysis only summarized eleven studies,
seven of which, with 1951 patients, were published articles and
the other four were conference abstracts with less convincing
evidence. Among the eleven studies, the sole outlier, identiﬁed
by funnel and forest plots, belonged to a conference abstract.
Another coexisting meta-analysis with eleven full-text studies
demonstrated that a lower level of vitamin D was signiﬁcantly
associated with a lower probability of SVR in CHC patients receiv-
ing Peg-IFNa/ribavirin therapy, especially when a cut-off value of
20 ng/ml for vitamin D deﬁciency was adopted [5]. Furthermore,
a low vitamin D status was also found to be associated with a
higher risk of advanced liver ﬁbrosis in these patients [5].
Numerous clinical evidence also suggested that vitamin D sup-
plementation might protect against disease progression and ele-
vate the SVR rate following treatment for CHC [6,7]. Recurrence
of hepatitis C after liver transplantation is universal worldwide
[8]. In addition to its association with primary CHC, vitamin D
insufﬁciency could also result in a low SVR in patients with recur-
rent hepatitis C following antiviral therapy while vitamin D sup-
plementation signiﬁcantly improves the probability of achieving
a SVR [8].
Potential mechanisms that link vitamin D and CHC are
complex and varied. Treatment with vitamin D reduces the extra-
and intracellular levels of hepatitis C virus (HCV) core antigen in a
dose-dependent manner [9] and produces calcitriol which could
markably inhibit HCV productions [10], suggesting that vitamin
D plays a natural antiviral role. In addition, the anti-
inﬂammatory effects by reducing several pro-inﬂammatory
factors like TNF-a, IFN-c, and IL-17, as well as the anti-ﬁbrotic
role of vitamin D [7], might also partly explain the beneﬁts of this
vitamin supplementation in CHC.
As there is a global high prevalence of hypovitaminosis D
among CHC patients, it is crucial to determine the association
between vitamin D status/vitamin D supplementation and
outcomes of CHC. Larger, random clinical trials are still required
to conﬁrm the important non-skeletal effects of vitamin D in
patients with CHC.
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Reply to: ‘‘Evidence supporting a beneﬁcial role of vitamin D
in chronic hepatitis C’’
To the Editor:
We thank Pang et al. for their interest in our recently published
systematic review and meta-analysis involving 2605 patients
which found no association between baseline 25-hydroxyvitamin
D level and sustained virologic response (SVR) to interferon-
based antiviral therapy in chronic hepatitis C infection [1]. They
are correct to highlight the inﬂuence of ethnicity on both vitamin
D status and genetic polymorphisms in key proteins involved in
vitamin D synthesis. The studies included in our meta-analysis
contained only a small number of participants of Asian [2] or
African-American [3] ethnicity, leading us to highlight the study’s
inability to adjust for ethnicity as one of its limitations.
With regards to the recently published meta-analysis by
García-Álvarez et al. [4] evaluating vitamin D status and response
to hepatitis C therapy, this study differs from ours in that it
includes those with HCV-HIV co-infection. Furthermore, we
believe this study has signiﬁcant methodological issues such as
the inclusion of three studies involving the same Italian cohort
of approximately 200 patients, and the exclusion of ﬁve large
studies [2,5–8] from Europe and Australia involving 1569
patients that were readily identiﬁable using the stated search
strategy. Our concerns about this study have recently been pub-
lished [9] and the validity of the study’s ﬁndings should be
viewed with caution.
Our meta-analysis only evaluates the relationship between
baseline vitamin D status and SVR. The impact of vitamin D sup-
plementation on outcomes to interferon-based antiviral therapy,
although interesting, is a different clinical question that has not
been deﬁnitively assessed in prospective, randomized controlled
trials. We agree that vitamin D has potential anti-viral, anti-
inﬂammatory, anti-ﬁbrotic and immunomodulatory actions rele-
vant to liver disease, which have been highlighted in a number
of pre-clinical studies [10]. However high quality prospective
clinical research studies are needed to support the hypothesis
that vitamin D deﬁciency may be responsible for the worse
outcomes in HCV related liver disease.
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